The Department of Health in Abu Dhabi (DoH) and M42 have launched the Abu Dhabi Biobank, the region’s largest hybrid cord blood bank, at the inaugural Abu Dhabi Global Healthcare Week 2024. Through this partnership, Abu Dhabi will be established as a leading hub for life sciences, which will improve the accessibility and effectiveness of healthcare.
With the goal of personalised healthcare, the Abu Dhabi Biobank functions as a fundamental bioasset that supports therapeutic interventions, research, drug discovery, and disease prevention. Stem cells from cord blood offer promise in treating various disorders, making the Biobank’s cord blood facility crucial for meeting demand and advancing regional innovation.
The Biobank, which has the ability to hold five million pan-human samples and 100,000 cord blood samples, will generate a diversified dataset that will improve access to better-matched stem cells worldwide. Its cutting-edge infrastructure promotes continuous medical advancement by guaranteeing safe storage for up to 30 years.
The cord blood bank enables expectant parents to save their baby’s stem cells, promoting national self-sufficiency and a healthier community at the same time. The initiative exemplifies Abu Dhabi’s dedication to progressive healthcare practices and the welfare of the community.
